Home Behandelprotocollen AML Richtlijnen en literatuur


Klik HIER voor de concept behandelrichtlijn AML (2018) van de HOVON Leukemie werkgroep.

Klik HIER voor het consensus document MRD bij AML (2018) van de ELN MRD werkgroep.


  1. Schuurhuis GJ et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131(12): 1275-1291. doi: 10.1182/blood-2017-09-801498
  2. Terwijn M et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013; 31(31): 3889-3897. e-pub ahead of print 2013/09/26; doi: 10.1200/JCO.2012.45.9628
  3. Zeijlemaker W et al. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia. Leukemia 2016; 30(3): 708-715. e-pub ahead of print 2015/09/17; doi: 10.1038/leu.2015.255
  4. Ivey A et al. Assessment of Minimal Residual Disease in Standard-Risk AML. The New England journal of medicine 2016. doi: 10.1056/NEJMoa1507471
  5. Ehinger M, Pettersson L. Measurable residual disease testing for personalized treatment of acute myeloid leukemia. APMIS 2019. e-pub ahead of print 2019/03/29; doi: 10.1111/apm.12926
  6. Wang Y et al. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood 2014; 124(12): 1880-1886. e-pub ahead of print 2014/08/02; doi: 10.1182/blood-2014-03-563403
  7. Döhner H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 129:424-447
  8. Arber D.A. et al. The 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 127:2391-2405
  9. Sorror M.L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 106: 2912-2919


Ga terug naar de AML homepage of lees meer over AML:

Ga terug naar de algemene homepage Behandelprotocollen